← Browse by Condition
Medical Condition
plasma cell myeloma refractory
Total Trials
2
Recruiting Now
2
Trial Phases
Phase 2, Phase 1
NCT06356571 Phase 2
Recruiting
A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
Enrollment
64 pts
Location
United States
Sponsor
Sanofi
NCT06630806 Phase 1
Recruiting
A Study to Investigate the Safety and Efficacy of SAR446523 Injected Subcutaneously in Adult Participants With Relapsed/Refractory Myeloma
Enrollment
87 pts
Location
United States, Austr...
Sponsor
Sanofi